Tamsulosin 106133-20-4
106463-17-6

inquire about Tamsulosin
Tamsulosin

Tamsulosin is an α1a-selective alpha blocker used in the symptomatic treatment of benign prostatic hyperplasia (BPH). Tamsulosin was developed by Yamanouchi Pharmaceuticals (now part of Astellas Pharma) and is marketed by various companies under licence, including Boehringer-Ingelheim and CSL. Tamsulosin hydrochloride extended-release capsules are marketed under the trade names Flomax, Flomaxtra and Urimax, though generic non-modified release capsules are still approved and marketed in many countries, such as Canada. The U. S. patent for Flomax expired October 2009. In Egypt it is marketed under the trade Omnic by Astellas pharma europe.

Mechanism

{{Dablink

 

Main article: Alpha blocker

read more [+]
Systematic (IUPAC) name: (R)-5-(2-(2-(2-ethoxyphenoxy)ethylamino)propyl)-2-methoxybenzenesulfonamide
Tamsulosin CAS number: 106133-20-4
106463-17-6
ATC code: G04CA02
PubChem: 129211
DrugBank: APRD00036
Formula: C20H28N2O5
Molecular mass: 408.51 g/mol
Tamsulosin Assay/Purity: Typically NLT 98%
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.